NASDAQ:LGND

Ligand Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy LGND

*Your capital is at risk

$234.40

+1.64 (+0.705%)

At Close: Jun 03, 2026

Ligand Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -51.06. In total, the insiders bought 188.75K and sold 50.59K LGND shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-51.06
● Buy	188.75K shares
● Sell	50.59K shares
33% Buy Activity Negligible or No Correlation
Sell Signal Medium Confidence Mar 04, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -51.06. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 01, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Reardon Andrew Clo & Secretary	Officer	5 000 Value: $261.4K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	200 Value: $46.1K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	1 216 Value: $279.0K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	584 Value: $133.5K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	400 Value: $90.7K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	1 432 Value: $323.6K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	677 Value: $152.5K
Jun 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	491 Value: $110.0K
Jun 01, 2026 Buy	Common Stock M-Exempt	Reardon Andrew Clo & Secretary	Officer	5 000 Value: $261.4K
May 27, 2026 Buy	Common Stock M-Exempt	Espinoza Octavio Chief Financial Officer	C-Suite Officer	764 Value: $48.6K
May 27, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Espinoza Octavio Chief Financial Officer	C-Suite Officer	972 Value: $51.4K
May 27, 2026 Buy	Employee Stock Option (right to buy) M-Exempt	Espinoza Octavio Chief Financial Officer	C-Suite Officer	764 Value: $48.6K
May 27, 2026 Buy	Common Stock M-Exempt	Espinoza Octavio Chief Financial Officer	C-Suite Officer	972 Value: $51.4K
May 13, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kozarich John W Director	Director	1 575 Value: $109.5K
May 13, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	1 575 Value: $352.0K
May 13, 2026 Buy	Common Stock M-Exempt	Kozarich John W Director	Director	1 575 Value: $109.5K
May 12, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	459 Value: $102.8K
May 12, 2026 Buy	Non-Qualified Stock Option (right to buy) M-Exempt	Kozarich John W Director	Director	459 Value: $31.9K
May 12, 2026 Buy	Common Stock M-Exempt	Kozarich John W Director	Director	459 Value: $31.9K
May 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	165 Value: $38.3K
May 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	105 Value: $24.4K
May 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	116 Value: $27.2K
May 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	80 Value: $18.2K
May 01, 2026 Sell	Common Stock S-Sale	Kozarich John W Director	Director	1 Value: $230
May 01, 2026 Sell	Common Stock S-Sale	Reardon Andrew Clo & Secretary	Officer	780 Value: $181.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LIGAND PHARMACEUTICALS INCORPORATED

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease ca...

Read Full Profile Here